Ipamorelin studies at AV Peptide

Human trials of ipamorelin

I bring recovery claims back to the bowel-resection trial. It tested a specific task: tolerating a meal after surgery, when bowel movement can be temporarily impaired. The median wait was 25.3 hours with ipamorelin and 32.6 hours with placebo. With p=0.15, the primary endpoint was missed. The study did not establish that ipamorelin restored eating sooner.

The numerical difference deserves to be reported, and so does the failed endpoint. Calling it a recovery success would give the drug a conclusion the trial did not reach. Calling it proof that no benefit could ever exist would go beyond the trial too. I’m left with an unsuccessful test of an appealing idea.

No ipamorelin-specific safety signal emerged in that short perioperative window. Adverse events were common in both groups recovering from surgery, and the observation period left long-term safety unanswered.

The hormone pulse

In the earlier healthy-male-volunteer study, intravenous ipamorelin produced a discrete growth hormone pulse, peaking at about forty minutes. The terminal half-life was approximately two hours. Those blood measurements established a short pharmacological response.

Ipamorelin acts at the ghrelin receptor, a different receptor from the one targeted by CJC-1295. That distinction makes the compound interesting well beyond a hormone trace: ghrelin signalling also involves appetite and digestion. It helps explain the bowel-recovery question. It supplies no demonstrated benefit for a CJC-1295 combination; the evidence here lacks a human outcome trial establishing that pair’s effects.

Ferret weight

The ferret study during cisplatin treatment separated outcomes that I would have been tempted to bundle together. Ipamorelin reduced later body-weight loss, while vomiting continued without an anti-emetic benefit. The related compound in the paper produced a different vomiting result.

Weight preservation therefore tells only part of this animal story. I’m glad both outcomes were measured: an account limited to the scale could make the animals’ condition sound more improved than the vomiting result allows. This experiment establishes neither a human chemotherapy benefit nor a treatment for nausea.

Rat skeletal growth

In adult female rats given ipamorelin, longitudinal bone growth increased with the study amount. Total circulating IGF-1, its binding proteins and the measured bone-turnover markers were unchanged.

Here a visible tissue outcome moved while the expected blood companion stayed quiet. Rat bone growth with unchanged total blood IGF-1 is the kind of mismatch I enjoy. It suggests that the simple chain from growth hormone to blood IGF-1 to growth leaves something unexplained in this setting. These were rat bones; the finding offers no evidence of adult human height gain.

Safety observations and anecdotes

Community reports describe deeper sleep, vivid dreams, easier recovery and a leaner appearance. They also describe flushing, tingling, water retention, hunger, lightheadedness and local irritation. These are anecdotal accounts, not clinical evidence; concurrent substances and unverified contents make attribution especially difficult.

The rat cardiovascular-toxicity paper tested a different ghrelin-receptor agonist, not ipamorelin. It found heart-muscle degeneration and cell death with longer exposure. That raises a class-level question requiring ipamorelin-specific investigation, without demonstrating that ipamorelin causes the same injury. The short human surgery trial cannot resolve it.

Ipamorelin has no approved human treatment use. Longer-term heart, glucose and cancer-safety questions remain, along with the quality uncertainties of research-labelled material and prohibition in drug-tested sport. “Selective” growth hormone release describes a pharmacological property; the whole compound still has to pass much broader safety testing before I’m convinced.